In connection with this proposal, Applicant has applied to acquire Integrity Securities, Inc., Hickory, North Carolina, and thereby engage in securities brokerage activities pursuant to section 225.28(b)(7)(i) of Regulation Y.

Board of Governors of the Federal Reserve System, February 3, 2006.

#### Robert deV. Frierson,

Deputy Secretary of the Board.
[FR Doc. E6–1741 Filed 2–8–05; 8:45 am]
BILLING CODE 6210–01–8

### **FEDERAL RESERVE SYSTEM**

### Notice of Proposals To Engage in Permissible Nonbanking Activities or To Acquire Companies That Are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y (12 CFR Part 225) to engage de novo, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Additional information on all bank holding companies may be obtained from the National Information Center Web site at <a href="www.ffiec.gov/nic/">www.ffiec.gov/nic/</a>.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than March 6, 2006.

### A. Federal Reserve Bank of Chicago (Patrick M. Wilder, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1414:

1. Mainsource Financial Group, Inc., Greensburg, Indiana; to acquire 100 percent of the voting shares of HFS Bank, F.S.B., Hobart, Indiana, and thereby operate a savings association pursuant to section 225.28(b)(4)(ii) of Regulation Y.

Board of Governors of the Federal Reserve System, February 3, 2006.

### Robert deV. Frierson,

Deputy Secretary of the Board. [FR Doc.E6–1742 Filed 2–8–06; 8:45 am] BILLING CODE 6210–01–S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the National Coordinator; American Health Information Community Consumer Empowerment Workgroup Meeting

**ACTION:** Announcing of meeting.

**SUMMARY:** This notice announces the second meeting of the American Health Information Community Empowerment Workgroup in accordance with the Federal Advisory Committee Act (Pub. L. 92–463, 5 U.S.C., App.).

**DATES:** February 21, 2006 from 1 p.m. to 5 p.m.

ADDRESSES: Hubert H. Humphrey Building (200 Independence Ave., SW., Washington, DC 20201), conference room 705A.

## **FOR FURTHER INFORMATION CONTACT:** http://www.hhs.gov/healthit.

**SUPPLEMENTARY INFORMATION:** A Web address for the meeting will be available at *http://www.hhs.gov/healthit.* 

Dated: February 1, 2006.

#### Dana Haza

Office of Programs and Coordination, Office of the National Coordinator.

[FR Doc. 06-1177 Filed 2-8-06; 8:45 am]

BILLING CODE 4150-24-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the National Coordinator; American Health Information Community Electronic Health Record Workgroup Meeting

**ACTION:** Announcement of meeting.

**SUMMARY:** This notice announces the second meeting of the American Health Information Community Electronic Health Record Workgroup in accordance with the Federal Advisory Committee Act (Pub. L. 92–463, 5 U.S.C., App.).

**DATES:** February 22, 2006 from 1 p.m. to 5 p.m.

ADDRESSES: Hubert H. Humphrey Building (200 Independence Ave., SW., Washington, DC 20201), conference room 425A.

**FOR FURTHER INFORMATION CONTACT:** http://www.hhs.gov/healthit.

**SUPPLEMENTARY INFORMATION:** A Web address for the meeting will be available at: http://www.hhs.gov/healthit.

Dated: February 1, 2006.

#### Dana Haza.

Office of Programs and Coordination, Office of the National Coordinator.

[FR Doc. 06–1178 Filed 2–8–06; 8:45 am]

BILLING CODE 4150-24-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the National Coordinator; American Health Information Community Chronic Care Workgroup Meeting

**ACTION:** Announcement of meeting.

**SUMMARY:** This notice announces the second meeting of the American Health Information Community Chronic Care Workgroup in accordance with the Federal Advisory Committee Act (Pub. L. 92–463, 5 U.S.C., App.).

**DATES:** February 23, 2006 from 1 p.m. to 5 p.m.

ADDRESSES: Cohen Building (330 Independence Ave., SW., Washington, DC 20201), Conference Room 5051.

**FOR FURTHER INFORMATION CONTACT:** http://www.hhs.gov/healthit.

**SUPPLEMENTARY INFORMATION:** A Web address for the meeting will be available at: http://www.hhs.gov/healthit.

Dated: February 1, 2006.

#### Dana Haza,

Office of Programs and Coordination, Office of the National Coordinator.

[FR Doc. 06–1179 Filed 2–8–06; 8:45 am]

BILLING CODE 4150-24-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the National Coordinator; American Health Information Community Biosurveillance Workgroup Meeting

**ACTION:** Announcement of meeting.

**SUMMARY:** This notice announces the second meeting of the American Health Information Community Biosurveillance Workgroup in accordance with the Federal Advisory Committee Act (Pub. L. 92–463, 5 U.S.C., App.)

**DATES:** February 24, 2006 from 1 p.m. to 5 p.m.

ADDRESSES: Cohen Building (330 Independence Ave., SW., Washington, DC 20201), Conference Room 5051.

**FOR FURTHER INFORMATION CONTACT:** http://www.hhs.gov/healthit.

**SUPPLEMENTARY INFORMATION:** A Web address for the meeting will be available at: http://www.hhs.gov/healthit.

Dated: February 1, 2006.

#### Dana Haza,

Office of Programs and Coordination, Office of the National Coordinator.

[FR Doc. 06–1180 Filed 2–8–06; 8:45 am] **BILLING CODE 4150–24–M** 

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Centers for Disease Control and Prevention

## Statement of Organization, Functions, and Delegations of Authority

Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772–76, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 70 FR 72842–72843, dated December 7, 2005) is amended to reflect the title change for the Division of Injury and Disability Outcomes, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention.

Section C–B, Organization and Functions, is hereby amended as follows:

Delete in its entirety the title for the Division of Injury and Disability Outcomes (CE6) and insert the Division of Injury Response (CTCE).

Dated: January 27, 2006

### William H. Gimson,

Chief Operating Officer, Centers for Disease Control and Prevention (CDC).

[FR Doc. 06–1199 Filed 2–8–06; 8:45 am]

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **Food and Drug Administration**

Advisory Committee on Special Studies Relating to the Possible Long-Term Health Effects of Phenoxy Herbicides and Contaminants (Ranch Hand Advisory Committee); Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Advisory Committee on Special Studies Relating to the Possible Long-Term Health Effects of Phenoxy Herbicides and Contaminants (Ranch Hand Advisory Committee).

General Function of the Committee: To advise the Secretary of Health and Human Services (the Secretary) and the Assistant Secretary for Health concerning its oversight of the conduct of the Ranch Hand study by the U.S. Air Force and provide scientific oversight of the Department of Veterans Affairs Army Chemical Corps Vietnam Veterans Health Study, and other studies in which the Secretary or the Assistant Secretary for Health believes involvement by the committee is desirable.

Date and Time: The meeting will be held on February 27, 2006, from 8:30 a.m. to 4 p.m.

Location: Food and Drug Administration, 5630 Fishers Lane, rm. 1066, Rockville, MD.

Contact Person: Leonard Schechtman, National Center for Toxicological Research (HFT-10), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-6696, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512560. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will discuss the following items: (1) Update on the Institute of Medicine's Air Force Health Study Disposition Study and related closure activities; (2) updates from the Air Force on the Viability Study, Compliance Study, Comprehensive Study, Mortality Update, Technical Reports, and External Collaborations.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by February 17, 2006. Oral presentations from the public will be scheduled on February 27, 2006, between approximately 11:30 a.m. and 12:30 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before February 17, 2006, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Leonard Schechtman at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: February 2, 2006.

### Jason Brodsky,

 $Acting \ Associate \ Commissioner \ for \ External \ Relations.$ 

[FR Doc. E6–1737 Filed2–8–06; 8:45 am] BILLING CODE 4160–01–S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **Food and Drug Administration**

[Docket No. 2004D-0385]

Guidance for Industry and Food and Drug Administration Staff; Class II Special Controls Guidance Document; Hepatitis A Virus Serological Assays; Availability

**AGENCY:** Food and Drug Administration,

HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of the guidance document entitled "Guidance for Industry and FDA Staff: Class II Special Controls Guidance Document: Hepatitis A Virus Serological Assays." The guidance document describes a means by which these in vitro diagnostic devices for the laboratory diagnosis of hepatitis A virus (HAV) may comply with the requirement of special controls for class II devices. Elsewhere in this issue of the Federal Register, FDA is publishing a final rule reclassifying these devices from class III (premarket approval) into class II (special controls). HAV serological assays are in vitro diagnostic devices used to test for specific antibodies to support the clinical laboratory diagnosis of HAV.

**DATES:** Submit written or electronic comments on this guidance at any time. General comments on agency guidance documents are welcome at any time.

**ADDRESSES:** Submit written requests for single copies on a 3.5" diskette of the guidance document entitled "Guidance for Industry and FDA Staff: Class II Special Controls Guidance Document: Hepatitis A Virus Serological Assays" to the Division of Small Manufacturers, International, and Consumer Assistance (HFZ-220), Center for Devices and Radiological Health, Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850. Send one selfaddressed adhesive label to assist that office in processing your request, or fax your request to 301-443-8818. See the **SUPPLEMENTARY INFORMATION** section for